Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

被引：9
|
作者：
Ansell, Stephen M. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
来源：
LANCET HAEMATOLOGY | 2019年 / 6卷 / 01期
关键词：
CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; NIVOLUMAB; PEMBROLIZUMAB; MULTICOHORT; BLOCKADE; FAILURE;
D O I：
10.1016/S2352-3026(18)30210-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E2 / E3
页数：2
相关论文
共 50 条
  • [41] Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
    Zhang, Xiao-Yin
    Collins, Graham P.
    CURRENT ONCOLOGY REPORTS, 2022, 24 (11) : 1477 - 1488
  • [42] Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classical Hodgkin Lymphoma
    Sanchez-Aguilera, Abel
    Montalban, Carlos
    De la Cueva, Paloma
    Sanchez-Verde, Lydia
    Morente, Manuel M.
    Garcia-Cosio, Monica
    Garcia-Larana, Jose
    Bellas, Carmen
    Provencio, Mariano
    Romagosa, Vicens
    Fernandez de Sevilla, Alberto
    Menarguez, Javier
    Sabin, Pilar
    Mestre, Maria J.
    Mendez, Miguel
    Fresno, Manuel F.
    Nicolas, Concepcion
    Piris, Miguel A.
    Garcia, Juan F.
    CANCER RESEARCH, 2006, 66 (08)
  • [43] Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma
    Bei Hu
    Ryan Jacobs
    Nilanjan Ghosh
    Current Hematologic Malignancy Reports, 2018, 13 : 543 - 554
  • [44] Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma
    Hu, Bei
    Jacobs, Ryan
    Ghosh, Nilanjan
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) : 543 - 554
  • [45] Checkpoint inhibitors in Hodgkin lymphoma
    Sasse, S.
    Momotow, J.
    Engert, A.
    INTERNIST, 2020, 61 (07): : 660 - 668
  • [46] Checkpoint inhibitors in Hodgkin lymphoma
    Sasse S.
    Momotow J.
    Engert A.
    best practice onkologie, 2021, 16 (12) : 558 - 566
  • [47] Leukocyte and eosinophil count at baseline predict outcome in relapsed or refractory classical Hodgkin lymphoma patients treated with immune checkpoint inhibitors
    Borchmann, S.
    Hude, I.
    Sasse, S.
    Broeckelmann, P.
    von Tresckow, B.
    Momotow, J.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 142 - +
  • [48] Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
    Lucchini, Elisa
    Rusconi, Chiara
    Levis, Mario
    Ricci, Francesca
    Santoro, Armando
    Ricardi, Umberto
    Volpetti, Stefano
    Matrone, Fabio
    Di Russo, Anna
    Caizzi, Manuela
    Schiattarella, Anna
    Zaja, Francesco
    HEMATOLOGY REPORTS, 2021, 13 (02)
  • [49] Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma
    Alexej Ballhausen
    Amin Ben Hamza
    Carlotta Welters
    Kerstin Dietze
    Lars Bullinger
    Hans-Peter Rahn
    Sylvia Hartmann
    Martin-Leo Hansmann
    Leo Hansmann
    Cancer Immunology, Immunotherapy, 2023, 72 : 515 - 521
  • [50] Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma
    Ballhausen, Alexej
    Ben Hamza, Amin
    Welters, Carlotta
    Dietze, Kerstin
    Bullinger, Lars
    Rahn, Hans-Peter
    Hartmann, Sylvia
    Hansmann, Martin-Leo
    Hansmann, Leo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (02) : 515 - 521
12345